Veru
Information

Veru

ISIN
US92536C1036
Ticker
VERU
ISIN
US92536C1036
Ticker
VERU
New Post
$12.59
- $0.10
-0.78%

Information

stock small cap
Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Employees
252
Industries
Biotechnology & Drugs
Sector
Consumer Staples

Community

Financials

1D span
$12.35
$12.65
52W span
$4.34
$17.50
Market Cap
$1.01B
Beta
-0.56747
Free Float
60.00M
Shares outstanding
80.07M

Analyst Ratings

Target Price
$34.00
This security is covered by 5 analysts
Buy
5
Hold
0
Sell
0

Dividends

Activities

Trending